Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Accumulated Expenses (2016 - 2026)

Eledon Pharmaceuticals filings provide 5 years of Accumulated Expenses readings, the most recent being $354000.0 for Q4 2017.

  • On a quarterly basis, Accumulated Expenses rose 608.0% to $354000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $354000.0, a 608.0% increase, with the full-year FY2017 number at $354000.0, up 608.0% from a year prior.
  • Accumulated Expenses hit $354000.0 in Q4 2017 for Eledon Pharmaceuticals, up from $102000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $5.0 million in Q4 2015 to a low of $50000.0 in Q4 2016.
  • Median Accumulated Expenses over the past 5 years was $1.5 million (2017), compared with a mean of $1.8 million.
  • Biggest five-year swings in Accumulated Expenses: tumbled 98.99% in 2016 and later surged 608.0% in 2017.
  • Eledon Pharmaceuticals' Accumulated Expenses stood at $2.2 million in 2013, then tumbled by 56.31% to $963000.0 in 2014, then skyrocketed by 414.43% to $5.0 million in 2015, then tumbled by 98.99% to $50000.0 in 2016, then surged by 608.0% to $354000.0 in 2017.
  • The last three reported values for Accumulated Expenses were $354000.0 (Q4 2017), $102000.0 (Q3 2017), and $1.5 million (Q2 2017) per Business Quant data.